Leukemic tumor burden significantly correlated with a higher risk for relapse (p=0.006), particularly with CD19-negative relapse, a higher incidence of treatment-related mortality, and a lower EFS, as previously reported (6–11). This evidence concerns the gene CD19 and neoplasm.